lyophilised powder comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-01-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid as supplied |
| Water solubility | Soluble | Dissolves in aqueous media |
| Typical storage temperature | -20 °C | Dry powder, desiccated, protected from light |
| Typical analytical method | RP-HPLC with mass spectrometry | Purity from peak area; mass for identity |
| Common synonyms | Tβ4 fragment; thymosin beta-4 fragment | Naming varies by supplier and catalogue |
Reconstitution practices affect downstream measurements. The dry powder is typically dissolved in sterile water or a suitable aqueous buffer, then mixed gently rather than vortexed at high speed. Visible particles or cloudiness suggest incomplete dissolution or contamination and should be investigated. For long-term storage, aliquots should be labeled with concentration, solvent, and date. Open questions include how different buffers alter peptide conformation and whether specific container materials adsorb the peptide. Those variables can change apparent concentration in assays even when the chemical identity is correct.
Lyophilized TB-500 is hygroscopic and should be kept dry before use. The usual storage recommendation for the solid is -20 °C, protected from light and moisture. Once dissolved, the peptide is less stable, and repeated freeze-thaw cycles can promote aggregation or degradation. Laboratories often divide a reconstituted solution into single-use aliquots and store them at -80 °C. Exact stability limits depend on buffer, pH, and concentration, so published data do not define a single universal condition.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
In March 2024, the Japanese Ministry of Health ordered stores to remove three RYR dietary supplements (Benikoji ColesteHelp, NaishiHelp Plus Cholesterol and Natto-kinase Sarasara Tsubu) produced by Kobayashi Pharmaceutical after reports of thousands made ill. Over a hundred people between the ages of 40 and 80 were hospitalized, and five had died as of 29 March, with four of them from kidney problems. There have been more than twelve thousand cases of health problems reported by users. The company said it uses a strain that does not produce citrinin. It has found puberulic acid in the recalled products and is looking into whether the substance might be linked to the fatalities. The suspect batch was manufactured in 2023. Some analysts have placed the blame on industry deregulation, intended to boost economic growth by facilitating the approval of health products. Benikoji products such as miso paste, crackers, food coloring, and a vinegar dressing made by other companies were also recalled. Kobayashi Pharmaceutical officially discontinued production of beni koji products on 8 August 2024.
Clinically, envenomation from coastal taipan bites commonly leads to neurotoxic effects, characterised by descending flaccid paralysis, ptosis, diplopia, ophthalmoplegia, bulbar weakness, intercostal weakness, and limb weakness. Severe cases require intubation. Venom-induced consumption coagulopathy is also common, characterised by clotting abnormalities and haemorrhage. Less-common effects are muscle damage (myotoxicity), characterised by elevated creatine kinase and myalgia (muscle pain), acute kidney injury (which can require dialysis in severe cases), and general systemic symptoms such as nausea and vomiting, diaphoresis (sweating), and abdominal pain. White cell count is commonly elevated and platelet count is often low. There is generally little local reaction at the site of the bite. The average venom yield from one milking is 120 mg, with a maximum recorded of 400 mg. The subcutaneous LD50 value of this species is 0.106 mg/kg, according to the Australian Venom and Toxin database, or 0.12 mg/kg, according to Engelmann and Obst (1981). The estimated lethal dose for humans is 3 mg. Its venom contains primarily taicatoxin, a highly potent neurotoxin, along with taipoxin, which has an LD50 of 2 μg/kg. 124 μg of the latter can kill a healthy 62 kg adult.
Wittman was reelected to the Virginia House of Delegates unopposed. On December 11, 2007, Wittman was first elected to the United States Congress to succeed the late congresswoman Jo Ann Davis, who died in October 2007. He was heavily favored in the special election due to the 1st's heavy Republican bent; it has been in Republican hands since 1977. The Independent candidate was Lucky Narain.
== Biology and biochemistry == S. haemolyticus is nonmotile, nonsporulating, facultatively anaerobic, and Gram-positive. Cells are typically coccus-shaped and range from 0.8 to 1.3 μm in diameter. It lives on a wide variety of substrates, including glucose, glycerol, maltose, sucrose, and trehalose. It also tests positive for acetoin production, arginine, dihydrolase, benzidine, catalase, hemolysis, and lipase; it tests negative for coagulase, DNase, ornithine decarboxylase and phosphatase
Sources: en.wikipedia.org
== Algorithms and software == Manual de novo sequencing is labor-intensive and time-consuming. Usually algorithms or programs come with the mass spectrometer instrument are applied for the interpretation of spectra.
Bromazolam (XLI-268) is a triazolobenzodiazepine (TBZD) which was first synthesised in 1976, but was never marketed. It has subsequently been sold as a designer drug, first being definitively identified by the EMCDDA in Sweden in 2016. It is the bromo instead of chloro analogue of alprazolam and has similar sedative and anxiolytic effects to it and other benzodiazepines. Bromazolam is a non subtype selective agonist at the benzodiazepine site of GABAA receptors, with a binding affinity of 2.81 nM at the α1 subtype, 0.69 nM at α2 and 0.62 nM at α5. The "common" dosage range for users of bromazolam was reported to be 1–2 mg, suggesting its potency is similar to alprazolam.
=== January === 2 January – Three people are killed after a fire breaks out at the New County Hotel in Perth. 16 January Teachers in Scotland begin 16 days of "rolling" strike action, with strikes occurring in two local authorities each day, beginning with Glasgow and East Lothian. The UK government announces it will block the Gender Recognition Reform (Scotland) Bill amid concerns about its impact on UK-wide equality law. 23 January – A fire breaks out in former department store Jenners on Princes Street, Edinburgh, resulting in the death of a firefighter and the injury of four others. 24 January – Following a trial at the High Court of Glasgow, transgender woman Isla Bryson is convicted of raping two women in 2016 and 2019, the offences having been committed before she began gender reassignment therapy. She is remanded to Cornton Vale women's prison, but moved to HMP Edinburgh two days later after First Minister Nicola Sturgeon says Bryson will not be allowed to serve her sentence at Cornton Vale. 28 January – Following controversy over the Isla Bryson case, the Daily Record reports that Tiffany Scott, a trans woman subject to an Order for Lifelong Restriction for stalking a 13-year-old girl, has successfully applied for a transfer from a men's prison to a women's facility. The Scottish Conservatives urge the Scottish Government to halt the move. 29 January – The Scottish Prison Service pauses the movement of all transgender prisoners while it carries out an "urgent review" into the transgender cases held in its custody.
== Theory == The use of micelles in high performance liquid chromatography was first introduced by Armstrong and Henry in 1980. The technique is used mainly to enhance retention and selectivity of various solutes that would otherwise be inseparable or poorly resolved. Micellar liquid chromatography (MLC) has been used in a variety of applications including separation of mixtures of charged and neutral solutes, direct injection of serum and other physiological fluids, analysis of pharmaceutical compounds, separation of enantiomers, analysis of inorganic organometallics, and a host of others. One of the main drawbacks of the technique is the reduced efficiency that is caused by the micelles. Despite the sometimes poor efficiency, MLC is a better choice than ion-exchange LC or ion-pairing LC for separation of charged molecules and mixtures of charged and neutral species. Some of the aspects which will be discussed are the theoretical aspects of MLC, the use of models in predicting retentive characteristics of MLC, the effect of micelles on efficiency and selectivity, and general applications of MLC. Reverse phase high-performance liquid chromatography (RP-HPLC) involves a non-polar stationary phase, often a hydrocarbon chain, and a polar mobile or liquid phase. The mobile phase generally consists of an aqueous portion with an organic addition, such as methanol or acetonitrile. When a solution of analytes is injected into the system, the components begin to partition out of the mobile phase and interact with the stationary phase.
==== Digital X-ray ==== Eastman Kodak filed the first patent for digital radiography in 1973. The first commercial CR (Computed Radiology) solution was offered by Fujifilm in Japan in 1983 under the device name CR-101. X-ray imaging plates are used in X-ray diagnostics to record the shadow image of X-rays. The first commercial digital X-ray system for use in dentistry was introduced in 1986 by Trophy Radiology (France) under the name Radiovisiography. Digital x-ray systems help reduce radiation exposure. Instead of film, the machines contain a scintillator that converts the incident X-ray photons either into visible light or directly into electrical impulses.
Sources: en.wikipedia.org
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.
The parent protein contains forty-three amino acids, while the fragment carries only a short motif from one region. The fragment can interact with actin in vitro, but it does not include the rest of the protein structure. Whether the shorter molecule behaves the same way in living systems is not settled.
Published controlled human studies are scarce, and most activity reports come from cell culture or animal models. Reviews often describe the evidence base as limited and methodologically uneven. Open questions include the relationship between route, dose, and measured outcomes.
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.